Get the Stockscreener App
5.325
6.97%
0.305
Polypid Ltd stock is traded at $5.325, with a volume of 326.43K.
It is up +6.97% in the last 24 hours and up +19.33% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$5.02
Open:
$5.12
24h Volume:
326.43K
Relative Volume:
2.92
Market Cap:
$102.96M
Revenue:
-
Net Income/Loss:
$-33.63M
P/E Ratio:
-2.7845
EPS:
-1.9124
Net Cash Flow:
$-47.63M
1W Performance:
+8.05%
1M Performance:
+19.33%
6M Performance:
+17.51%
1Y Performance:
+53.43%
1-Day Range:
$5.02
$5.38
1-Week Range:
$4.91
$5.3799
52-Week Range:
$3.06
$5.3799
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
5.37 | 97.40M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
528.23 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.45 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.34 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.28 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
Price to sales forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
PolyPid Ltd. Actuals & Estimates (NASDAQ:PYPD) - TradingView
PolyPid Ltd. Actuals & Estimates (FWB:2PV) - TradingView
2PV Forecast — Price Target — Prediction for 2027 - TradingView
Lilly’s $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid’s Asset is Hiding in Plain Sight - TipRanks
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Raises Target Price to $9 - Moomoo
PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PolyPid Ltd (PYPD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PolyPid Ltd (PYPD) Valuation: PE, PB & Fair Value Analysis - TradingKey
PolyPid Ltd (PYPD) Institutional Confidence - TradingKey
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PolyPid Ltd Stock (US70450B1035): modest move as market awaits next catalyst - AD HOC NEWS
PYPD Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineNew Analyst Coverage - newsline.com
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PolyPid Ltd. (PYPD) Shares Edge Higher as Support Holds, Resistance in FocusTRIN Signal - newsline.com
PYPD Technical Analysis & Stock Price Forecast - Intellectia AI
PolyPid schedules annual and extraordinary shareholder meeting for July 15 By Investing.com - Investing.com Nigeria
PolyPid Sets July 15, 2026 Shareholder Meeting to Vote on Board, Auditor and Equity Grants - TipRanks
PolyPid schedules annual and extraordinary shareholder meeting for July 15 - Investing.com India
PolyPid (PYPD) schedules July 15, 2026 meeting on director, auditor and option approvals - Stock Titan
When Can We Expect A Profit From PolyPid Ltd. (NASDAQ:PYPD)? - simplywall.st
PYPD Q1 2026 Earnings: Narrower-than-Expected Loss Drives 20.81% Surprise; Shares Dip Despite ProgressForward EPS Estimate - newsline.com
PolyPid Ltd. (PYPD) Shares Slide 6.8% as Stock Approaches Key Support at $4.27Factor Valuation - newsline.com
PYPD Q1 2026 Earnings: Pre-Revenue Biotech Narrows Loss, Stock Slides on No Commercial MilestonesQuarterly Financial Update - newsline.com
PolyPid Stock Barely Moves After FDA Filing, But a 2027 Decision Now Looms - Bez Kabli
PYPD Q1 2026 Earnings: Narrower Loss Surprises as Key Pipeline Progress Remains on TrackGuidance Accuracy Score - newsline.com
PYPD Q1 2026 Earnings: Narrower Than Expected Loss Drives Positive Surprise Despite Stock DipEarnings Revision Downgrade - newsline.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), IN8bio (INAB) and PolyPid (PYPD) - The Globe and Mail
PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100 - marketscreener.com
PolyPid Files NDA with FDA for Lead Infection-Prevention Drug D-PLEX100 - TipRanks
PolyPid completes NDA submission for surgical infection drug - Investing.com
PolyPid completes NDA submission for surgical infection drug By Investing.com - Investing.com Canada
PolyPid (Nasdaq: PYPD) files FDA NDA for D-PLEX100 infection drug - Stock Titan
New surgical infection drug from PolyPid heads to FDA decision in 2027 - Stock Titan
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ - GlobeNewswire
PolyPid Ltd stock (US70450B1035): Nasdaq-listed biotech sees quiet trading as investors await next c - AD HOC NEWS
PYPD Q1 2026 Earnings: Narrower Net Loss Beats Expectations as Clinical Pipeline AdvancesFinancial Data - The Legal Advocate
PolyPid Ltd. (PYPD) Q1 2026 Earnings: Narrower-than-Expected Loss on Strong Expense ControlMargin Guidance - The Legal Advocate
PolyPid Ltd. (PYPD) Edges Lower, Testing Key Support Near $4.52Delta Hedging - The Legal Advocate
PYPD Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesGuidance vs Actual - The Legal Advocate
PYPDPolypid Ltd Stock Price and Quote - Finviz
PolyPid Shares Edge Lower as Stock Nears Key Support ZoneShort Term Trading Ideas - The Legal Advocate
PolyPid Shares Slide Amid Light Trading, Testing Key Support Levels (PYPD)Market Cap Weight - The Legal Advocate
PolyPid Q1 earnings call highlights - MSN
PolyPid (PYPD) Jumps 3.93% as Stock Approaches Key Resistance LevelSupport Level Bounce - Newser
PYPD Q1 2026 Earnings: EPS Beat on Operational Discipline, But Revenue Remains AbsentEarnings Season Review - Newser
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference - GlobeNewswire
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):